CD86 and cancer: Consistent with previous studies conducted with different cancer types [6, 7, 14, 35, 36], CD11c+ TIDC isolated from 4T1- or LLC-tumor bearing mice exhibit an altered phenotype characterized by intermediary expression of costimulatory (CD80, CD86, and CD40) and MHC II molecules, produce low amounts of the proinflammatory cytokine IL-12, and are poor inducers of T lymphocyte proliferation.